

**CRITICAL LIMB ISCHEMIA (CLI) NON-RESPONDERS:
PATIENTS WHO DO NOT RESPOND TO REVASCULARIZATION,
FACTORS THAT IDENTIFY NON-RESPONSE
AND NON-RESPONDER PREVALENCE AND MARKETS**

Mary L. Yost
404-520-6652
THE SAGE GROUP

THE SAGE GROUP, LLC
RESEARCH AND CONSULTING
23 Ridge Rd
Beaufort SC 29907

Copyright Pending
2020

All rights reserved, including the right of reproduction
in whole or in part in any form.

INDEX OF TABLES

Table 1: Critical Limb Ischemia Risk Factors Associated with Non-Response to Revascularization	7.
Table 2: Critical Limb Ischemia Risk Factors for Non-Response and Percentage Prevalence of Non-Responders	8.
Table 3: Critical Limb Ischemia Non-Responders 2020 Prevalence Based on Presence of Each Risk Factor	13.
Table 4: Critical Limb Ischemia Non-Responders 2020 Market Based Presence of on Each Risk Factor	17.
Table 5: Critical Limb Ischemia 2015-2030 Prevalence	21.
Table 6: Critical Limb Ischemia Non-Responders 2015-2030 Prevalence Based on Presence of Microvascular Disease	26.
Table 7: Critical Limb Ischemia Non-Responders 2015-2030 Market Based on Presence of Microvascular Disease	27.
Table 8: Critical Limb Ischemia Non-Responders 2015-2030 Prevalence Based on Presence of Diabetes and Chronic Kidney Disease	33.
Table 9: Critical Limb Ischemia Non-Responders 2015-2030 Market Based on Presence of Diabetes and Chronic Kidney Disease	33.
Table 10: Critical Limb Ischemia Definition of Foot and Below-the-Ankle Atherosclerotic Disease	34.
Table 11: Critical Limb Ischemia Prevalence of Any Foot Artery Disease (FAD)	35.
Table 12: Peripheral Artery Disease Prevalence of Foot Artery Disease (FAD)	36.
Table 13: Peripheral Artery Disease Dialysis and Diabetes Predict Disease Location Below-the-Knee and in the Foot	37.
Table 14: Critical Limb Ischemia Non-Responders 2015-2030 Prevalence Based on Presence of Small Artery Disease	39.
Table 15: Critical Limb Ischemia Non-Responders 2015-2030 Market Based on Presence of Small Artery Disease	39.
Table 16: Critical Limb Ischemia Percentage of Patients with Non-Patent Pedal Arch	40.
Table 17: Critical Limb Ischemia Non-Responders 2015-2030 Prevalence Based on Presence of Renal Foot	43.

Table 18: Critical Limb Ischemia Non-Responders 2015-2030 Market Based on Presence of Renal Foot 44.

Table 19: Critical Limb Ischemia Non-Responders 2015-2030 Prevalence Based on Presence of Ischemic and Neuroischemic Ulcers 46.

Table 20: Critical Limb Ischemia Non-Responders 2015-2030 Market Based on Presence of Ischemic and Neuroischemic Ulcers 46.

Table 21: Critical Limb Ischemia Non-Responders 2015-2030 Prevalence Based on Presence of Below-the-Ankle Disease in Diabetics with Ischemic and Neuroischemic Ulcers 48.

Table 22: Critical Limb Ischemia Non-Responders 2015-2030 Market Based on Presence of Below-the-Ankle Disease in Diabetics with Ischemic and Neuroischemic Ulcers 48.

CONTACT INFORMATION

Mary L. Yost
President
Telephone (404) 520-6652
yost@thesagegroup.us